Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Kura Oncology (KURA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 654,983
  • Shares Outstanding, K 37,970
  • Annual Sales, $ 0 K
  • Annual Income, $ -35,430 K
  • 36-Month Beta 4.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.41
  • Number of Estimates 5
  • High Estimate -0.40
  • Low Estimate -0.43
  • Prior Year -0.38
  • Growth Rate Est. (year over year) -7.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.30 +6.75%
on 09/18/18
20.85 -16.55%
on 09/04/18
-2.05 (-10.54%)
since 08/24/18
3-Month
16.30 +6.75%
on 09/18/18
22.00 -20.91%
on 08/02/18
-0.60 (-3.33%)
since 06/25/18
52-Week
12.10 +43.80%
on 10/27/17
24.02 -27.58%
on 02/20/18
+4.40 (+33.85%)
since 09/25/17

Most Recent Stories

More News
Kura Oncology: 2Q Earnings Snapshot

SAN DIEGO (AP) _ Kura Oncology Inc. (KURA) on Monday reported a loss of $14.7 million in its second quarter.

KURA : 17.40 (+0.87%)
Kura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update

- Update from ongoing Phase 2 trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) to be presented at ESMO 2018 -

KURA : 17.40 (+0.87%)
Kura Oncology, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Kura Oncology, Inc. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern Time.

KURA : 17.40 (+0.87%)
Kura Oncology Appoints Marc Grasso, M.D., as Chief Financial Officer and Chief Business Officer

Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the appointment of Marc Grasso, M.D., as Chief...

KURA : 17.40 (+0.87%)
Kura Oncology to Report Second Quarter 2018 Financial Results

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report second quarter 2018 financial...

KURA : 17.40 (+0.87%)
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the closing of its previously announced underwritten...

KURA : 17.40 (+0.87%)
Kura Oncology Announces Pricing of $67 Million Public Offering of Common Stock

Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of an underwritten public offering...

KURA : 17.40 (+0.87%)
Kura Oncology Announces Commencement of Public Offering of Common Stock

Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has commenced an underwritten public...

KURA : 17.40 (+0.87%)
Kura Oncology Appoints Chief Operating Officer, Expands Clinical Development Team as Company Prepares for First Registration-Directed Trial

- John Farnam appointed to newly created position of Chief Operating Officer -

KURA : 17.40 (+0.87%)
Kura Oncology to Present at JMP Securities Life Sciences Conference

Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., Kura's President...

KURA : 17.40 (+0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More Share

Trade KURA with:

Business Summary

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL,...

See More

Key Turning Points

2nd Resistance Point 18.28
1st Resistance Point 17.77
Last Price 17.40
1st Support Level 16.77
2nd Support Level 16.28

See More

52-Week High 24.02
Fibonacci 61.8% 19.47
Fibonacci 50% 18.06
Last Price 17.40
Fibonacci 38.2% 16.66
52-Week Low 12.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar